Month: October 2018

J & J Submits for Esketamine Nasal Spray Approval in America

Janssen has submitted a filing for approval of Esketamine with the United States Food and Drug Administration for treating depression. About 30-40% of people do not respond to current depression treatments, which results in major depression disorder leading the cause of disability all over the world. The recent filing needs to prove the drug is safe and will be beneficial for the intended recipients. What is Ketamine? Before taking a look at how ketamine works, let’s talk about what it is. Classified as a dissociative anesthetic, along with PCP and nitrous oxide, ketamine is a class III scheduled drug only approved for hospital and medical setting use. At high doses, the drug is used for anesthesia purposes, while at lower doses it produces hypnotic effects, altered perception, and pain re...

Skip to toolbar